| Study population, n (%) | Hypercholesterolaemia (LDL-C ≥5.0 mmol/l), n % | |
|---|---|---|
| Total | 2382 (100.0) | 237 (9.9) |
| Age, years, mean (IQR) | 52.6 (19.1–98.9) | 63.9 (26.9–93.4) |
| Sex, Male | 1047 (44.0) | 111 (46.8) |
| Cardiovascular disease | ||
| Ischaemic heart disease | 116 (4.9) | 31 (13.1) |
| MI | 41 (35.3) | 9 (29.0) |
| AP | 56 (48.3) | 18 (58.1) |
| CHF | 30 (25.9) | 5 (16.1) |
| PCI | 11 (9.5) | 2 (6.5) |
| CABG | 9 (7.8) | 1 (3.2) |
| AP (no IHD) | 49 (2.1) | 8 (3.4) |
| Cerebrovascular disease | 103 (4.3) | 26 (11.0) |
| Stroke | 70 (68.0) | 19 (73.1) |
| TCI | 47 (45.6) | 10 (38.5) |
| Peripheral artery disease | 49 (2.1) | 10 (4.2) |
| Comorbidity | ||
| Hypertension | 454 (19.1) | 115 (48.5) |
| Diabetes | 146 (6.1) | 30 (12.7) |
| Type 1 | 11 (7.5) | 2 (6.7) |
| Type 2 | 135 (92.5) | 28 (93.3) |
| Hyperthyroid disease | 60 (2.5) | 9 (3.8) |
| Hypothyroid disease | 116 (4.9) | 22 (9.3) |
| Liver disease | 60 (2.5) | 20 (8.4) |
| Viral hepatitis | 18 (0.8) | 2 (0.8) |
| Alcohol abuse | 100 (4.2) | 18 (7.6) |
| Obesity | 129 (5.4) | 14 (5.9) |
| Medications | ||
| Statin | 293 (12.3) | 119 (50.2) |
| Ezetimibe | 8 (0.3) | 4 (1.7) |
| PCSK9 inhibitor | 1 (0.04) | 1 (0.4) |
| ACE inhibitor | 205 (8.6) | 33 (13.9) |
| ATII antagonist | 125 (5.2) | 21 (8.9) |
| Beta blockers | 217 (9.1) | 37 (15.6) |
| Calcium channel blockers | 270 (11.3) | 49 (20.7) |
| Diuretics | 244 (10.2) | 54 (22.8) |
Baseline characteristics of the study population and those individuals with LDL-C ≥5.0 mmol/l. All data obtained exclusively through electronic screening of the patient records. ACE = angiotensin converting enzyme. AP = angina pectoris. ATII = angiotensin II receptor. CABG = coronary artery by-pass grafting. CHF = congestive heart failure. IHD = ischaemic heart disease. MI = myocardial infarction. PCI = percutaneous intervention. PCSK9 = proprotein convertase subtilisin/kexin type 9. TCI = transitory cerebral ischaemia.